Erlotinib 150mg/day

2 trials

Sponsors

Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL Department of Respiratory Medicine, Itabashi central medical center

Conditions

lung adenocarcinomanon-squamous non-small cell lung cancer

Phase 2

Phase II study of Erlotinib monotherapy in EGFR mutation-negative lung adenocarcinoma excluded biomarkers against EGFR-TKI treatment.

Active, not recruitingJPRN-UMIN000011411

Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL Department of Respiratory Medicinelung adenocarcinoma

Start: 2013-05-01Target: 23Updated: 2026-06-29

A phase 2 Study of the efficay and safty of erlotinib therapy for 3/4 stage EGFR gene mutation positive EGFR-TKI untreated non-small cell lung cancer

Active, not recruitingJPRN-UMIN000011986

Itabashi central medical centernon-squamous non-small cell lung cancer

Start: 2013-08-31Target: 21Updated: 2026-06-29